Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasiblity study.
The purpose of this study was to evaluate the feasibility and the outcome impact of cytoreductive surgery (CRS) followed by intraperitoneal hyperthermic perfusion (IPHP) in patients affected by uterine sarcoma (US). Ten US patients were treated with CRS+IPHP (closed technique, cisplatin+mitomycin C or cisplatin+doxorubicin). Median follow-up was 25 months (range: 2-61). Five patients received preoperative chemotherapy. Nine cases underwent optimal CRS. Five-year overall and progression-free survivals were 65% and 30%, respectively. There was no operative morbidity, nor mortality and nor toxicity. Six patients presented disease progression. CRS+IPHP proved feasible and safe, with encouraging outcome results, warranting confirmation by further prospective controlled trials.
Kusamura
S
S
Department of Gynecologic Oncology, Istituto Nazionale Tumori, Milan, Italy. skusamura@hotmail.com
Raspagliesi
F
F
Baratti
D
D
Gronchi
A
A
Casali
P
P
Deraco
M
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D012509:Sarcoma / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D014594:Uterine Neoplasms / Q000401:mortality / Q000628:therapy*
D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin